Abstract
The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.
| Original language | English |
|---|---|
| Pages (from-to) | 291-296 |
| Number of pages | 6 |
| Journal | British Journal of Cancer |
| Volume | 103 |
| Issue number | 3 |
| Early online date | 6 Jul 2010 |
| DOIs | |
| Publication status | Published - 27 Jul 2010 |
Keywords
- Aged
- Androstadienes
- Antineoplastic Agents
- Aromatase Inhibitors
- Breast Neoplasms
- Bridged Compounds
- Case-Control Studies
- Cytokines
- Estrogens
- Female
- Humans
- Inflammation
- Middle Aged
- Musculoskeletal Diseases
- Postmenopause
- Syndrome
- Tamoxifen
- Taxoids
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver